索磷布韦联合达拉他韦治疗丙型肝炎相关晚期失代偿性肝病(MELD≥15)患者
该前瞻性研究纳入108例MELD≥15的丙型肝炎失代偿期肝硬化患者,接受索磷布韦/达拉他韦±利巴韦林治疗24周。意向性分析SVR12率为70%(76/108),符合方案分析为76%(56/78)。获得SVR12者MELD和Child-Pugh评分显著下降(P<.001)。基线MELD≥20者移植风险显著增高(OR 13.8,95%CI 2.78-69.04)。
要点
- 索磷布韦/达拉他韦治疗晚期失代偿丙肝肝病,意向性分析SVR12率为70%。
- 获得SVR12者中位MELD从16降至14,Child-Pugh从10降至8(P<.001)。
- 基线MELD≥20者需移植的OR为13.8(95%CI 2.78-69.04)。
核心结论
- 索磷布韦/达拉他韦在晚期肝病中的SVR12率低于代偿期肝病。
- 尽管治疗可改善多数患者的MELD和Child-Pugh评分,但相当比例患者仍会死亡或需要移植。
- 对于MELD≥20者,作者认为可能最好延迟治疗至移植后。
研究设计与样本
- 前瞻性收集在澳大利亚患者供药项目(TOSCAR)下开始索磷布韦/达拉他韦治疗24周的患者数据。
- 共纳入108例患者(男79例/女29例;中位年龄56岁;Child-Pugh 10分;MELD 16分;基因1型55例/3型47例)。
- 所有患者均为MELD评分≥15的失代偿性丙型肝炎肝硬化。
- 108例中2例同时接受利巴韦林。
主要发现
- 意向性分析SVR12率为70%(76/108)。
- 78例完成24周治疗,符合方案分析中56例获得SVR12(76%)。
- 基因1型SVR12率为80%,基因3型为69%。
- 30例未能完成治疗。
- 获得SVR12者中位MELD从16(IQR 15-17)降至14(12-17),Child-Pugh从10(9-11)降至8(7-9),P<.001。
临床怎么用
- 作者认为,对于MELD≥20的患者,可能最好延迟治疗至移植后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antiviral therapy for hepatitis C has the potential to improve liver function in patients with decompensated cirrhosis. AIMS: To examine the virological response and effect of viral clearance in patients with decompensated hepatitis C cirrhosis all with MELD scores ≥15 following sofosbuvir/daclatasvir ± ribavirin. METHODS: We prospectively collected data on patients who commenced sofosbuvir/daclatasvir for 24-weeks under the Australian patient supply program (TOSCAR) and analysed outcomes including sustained viral response at 12 weeks (SVR12), death and transplant. RESULTS: 108 patients (M/F, 79/29; median age 56years; Child-Pugh 10; MELD 16; genotype 1/3, 55/47) received sofosbuvir/daclatasvir and two also received ribavirin. On intention-to-treat, the SVR12 rate was 70% (76/108). Seventy-eight patients completed 24-weeks therapy. SVR12 was achieved in 56 of these patients on per-protocol-analysis (76%). SVR12 was 80% in genotype 1 compared to 69% in genotype 3. Thirty patients failed to complete therapy. In patients achieving SVR12, median MELD and Child-Pugh fell from 16(IQR15-17) to 14(12-17) and 10(9-11) to 8(7-9), respectively (P<.001). In those who died, MELD increased from 16 to 23 at death (P=.036). Patients who required transplantation had a significantly higher baseline MELD (20) compared to those patients completing treatment (16) (P=.0010). The odds ratio for transplant in patients with baseline MELD ≥20 was 13.8(95%CI 2.78-69.04). CONCLUSIONS: SVR12 rates with sofosbuvir/daclatasvir in advanced liver disease are lower than in compensated disease. Although treatment improves MELD and Child-Pugh in most patients, a significant proportion will die or require transplantation. In those with MELD ≥20, it may be better to delay treatment until post-transplant.
引用
- McCaughan GW, Thwaites PA, Roberts SK, et al. Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15). Aliment Pharmacol Ther. 2017. PMID: 29205432. doi:10.1111/apt.14404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。